Member Info for Dr_Horrible

“In the coming months, based on its current level of cash, the Group may need to raise further equity finance or potentially new loan finance, subject in large part to the size / volume of new production runs of Fruitflow II SD which the Company may need to commission, with larger production runs inevitably requiring more cash at the outset”

So the stock we have bought and the production run we will have just done will be gone and we’ll need the cash flow for much bigger runs ‘in the coming months’.

Fair to say when it happens it will be transformational.

Next update is September 30th 2025.

FF+O3 revenue has dropped quite a bit.

I doubt they would wait, that would create a crazy long timeline.

It’s an international patent with priority date June 2023.

https://patentscope.wipo.int/search/docs2/iasr/WO2024260450/pdf/QUVIGVnNopeQjXwKjjZ69HS40Mo4Ly5dMln5jW93UXs?filename=CN2024100669-IASR.pdf

A market cap of £14m seems high for the current revenue and continued losses. However, we are forecasting substantial multiples of the current FF sales (>£1m) for the current pipeline, then substantial multiples for China, then likely substantial multiples for the new DSM Gut Health stream. What is a substantial multiple? I would guess at least 10x. Then we are working on FF as a drug, which will give it access to a massive market. Also PXS selling FF direct will make some good profit. Given all this and having stock and money for the next FF run, I think the risks are now very low and the potential upside is huge.

M how much stock do we think was likely purchased? Maybe £300k? And we need a new FF run in the early part of the year (Jan - March) to meet increased demand. That’s very positive indeed. It should be an interesting year. Looks like we are moving into profit and we still have China come.

We must be getting a credit of £564,033 in the results in April (reported next September)? Maybe more clarification in the update on 31st Dec this year too. Hope so, otherwise we’ve been diddled.

DD77, I misread the RNS. However, looking at it again I am confused. The shares are for the royalty payment to end of December 2024. However, we have already accounted for that payment under our Cost Of Goods. So had we accounted for it in our finances, but not actually paid them the money yet? We seem to be forking out for something we have already paid for?

I think we are on track for £1.5m FF revenue, plus £150k FF+O3. We have now stopped paying DSM money, have stock for the next few months and a good chunk of change to fund a sizeable FF run. This will also mean that when BH make an initial order we can supply a good amount immediately whilst we get another batch cooking. Today should mark the end of needing more money and we should be in profit from here onwards. We won’t see that profit for a while, but we should now be making money.

Well at least that’s the funding sorted now and moving to profitability sooner.

They could be FF approvals for blood pressure or lipid reduction. We’ll find out one day, more likely via Gix than RNS.

Https://hpachina.org/2024/07/09/analysis-of-china-dietary-supplement-registration-in-the-first-half-of-2024/

Here’s to 25 pence per share, cheers :)

Odd that they didn’t opt for a full dose.

Powdered tomato concentrate 100mg

The international patent application is now in the National phase, so it will be registered in each country. That means all the searches are completed.

https://www.wipo.int/pct/en/faqs/faqs.html

Given that just a few larger trades positively impacts the share price so much, it’s a reminder that when profits eventually come the share price will, I hope, go up a lot. There will be a massive increase in demand for shares and we ain’t selling.

I thought they said the CEO "was putting in way in excess of the average daily grift"

Hopefully we are very near. Perhaps a nice Christmas present for us.

Maybe by 2030 SAMR will have pulled their finger out.